IEX •
Healthcare •
Biotechnology •
Quote as of 06/12/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeIEX
Market Capitalization22 mln
Float8.58 mln
Earnings Date08/17/2026
Piotroski F-Score
3
/ 9
Below average
1-Year Forecast
22.75
Transformational upside
Relative Strength
0
/ 100
Severely lagging
Debt / Equity
0.00
Debt-free
ROE
-77.56
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Atossa Therapeutics is a Seattle-based company focused on developing new treatments for breast cancer and other conditions where effective options are limited. Its primary drug in development, oral endoxifen, is currently in Phase II clinical trials aimed at both treating and preventing breast cancer. The company is also working on immunotherapy programs as part of its broader research efforts. Founded in 2008, Atossa has been dedicated to advancing women's health through innovative medicine.
